Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

and early efficacy data on the product.

The deal with Roche was a key element in ThromboGenics' corporate strategy, and has allowed the Company to focus on developing the other attractive products in its pipeline, particularly its lead product, microplasmin. The upfront payment from Roche has also provided a significant portion of the funds needed for the microplasmin Phase III program, which will evaluate the drug in a number of back of the eye disease indications.

TB-402 (Anti-Factor VIII) - A Unique, Long-acting Anti-coagulant

ThromboGenics is developing TB-402 in collaboration with BioInvent International. TB-402 is a novel human antibody which partially blocks Factor VIII, an essential blood clotting factor. TB-402 is being developed as an anticoagulant for the treatment and prevention of deep vein thrombosis (DVT) and atrial fibrillation. It is anticipated that TB-402 will be a novel, safe, and affordable anticoagulant, providing extended activity with a single dose, with ease of administration and compliance superior to alternative anticoagulants.

The Phase I interaction studies, which were successfully completed in the second quarter of 2008, have shown that TB-402 has the potential to be a safe and well controlled treatment for diseases where the prevention of blood clots is imperative. As a result of the encouraging results from these studies, TB-402 is expected to begin its Phase II clinical development by the end of 2008.

ThromboGenics will provide a further update when the Company reports its 2008 Full Year Results on 12th March, 2009.
For further information please contact:

ThromboGenics:

Patrik De Haes, CEO, Tel : +32-16-75-13-10,

patrik.dehaes@thrombogenics.com

Chris Buyse, CFO, Tel : +32-16-75-13-10,


'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Quantum Center at Skolkovo) and Mario Ziman (Masaryk ... of Physics in Bratislava, Slovakia) have found a ... through an amplifier and, conversely, when transmitting a ... an article published in the journal Physical ... particles are considered to be the basis of ...
(Date:7/23/2014)... Last year, Formedix celebrated ... global provider of data management solutions for clinical trials. ... system for electronic data capture (EDC) and clinical data ... study execution tools added TrialMaster to its Transform for ... of Transform for TrialMaster, is being released this week, ...
(Date:7/23/2014)... 23, 2014 DuPont Pioneer announced today ... vice president of Agricultural Biotechnology (ABT), effective July 21, ... served most recently as president, chief executive officer and ... leadership in the seed and crop protection industry to ... E. Schickler , president of DuPont Pioneer. “I am ...
(Date:7/23/2014)... PARK, Calif. , July 23, 2014  Sofinnova ... investment firm, today announced the closing of Sofinnova Venture ... million and in excess of the initial fund target ... helping entrepreneurs build successful biotechnology companies. Consistent with recent ... with promising later stage clinical programs, along with select ...
Breaking Biology Technology:Scientists find way to maintain quantum entanglement in amplified signals 2Scientists find way to maintain quantum entanglement in amplified signals 3Scientists find way to maintain quantum entanglement in amplified signals 4Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Sofinnova Raises $500 Million Biotech Venture Fund 2
... , SAN MARINO, Calif., Aug. 11 ... technology company Viral Genetics (Pink Sheets: VRAL), will address the 4th ... Her presentation will highlight the potential for combining chemotherapy with compounds ... the energy needed to repair chemotherapy induced DNA damage. This repair ...
... SHANGHAI, Aug. 11 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc.,(NYSE: ... outsourcing company serving the,pharmaceutical, biotechnology, and medical device industries, ... its financial results for,second-quarter 2009. , ... 2009 Highlights, -- Net revenues totaled ...
... Del., Aug. 11 ParagonRx, a healthcare consulting leader in ... a free Webinar-on-Demand created by the Drug Safety Executive Council ... officers in healthcare companies. , , The ... g onrx.com/experience/webinars/ . , , ...
Cached Biology Technology:Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium 2Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium 3WuXi PharmaTech Announces Second-Quarter 2009 Results 2WuXi PharmaTech Announces Second-Quarter 2009 Results 3WuXi PharmaTech Announces Second-Quarter 2009 Results 4WuXi PharmaTech Announces Second-Quarter 2009 Results 5WuXi PharmaTech Announces Second-Quarter 2009 Results 6WuXi PharmaTech Announces Second-Quarter 2009 Results 7WuXi PharmaTech Announces Second-Quarter 2009 Results 8WuXi PharmaTech Announces Second-Quarter 2009 Results 9WuXi PharmaTech Announces Second-Quarter 2009 Results 10WuXi PharmaTech Announces Second-Quarter 2009 Results 11WuXi PharmaTech Announces Second-Quarter 2009 Results 12WuXi PharmaTech Announces Second-Quarter 2009 Results 13WuXi PharmaTech Announces Second-Quarter 2009 Results 14WuXi PharmaTech Announces Second-Quarter 2009 Results 15WuXi PharmaTech Announces Second-Quarter 2009 Results 16
(Date:7/23/2014)... Canada has issued a high health risk warning for ... the region due to forest fires. In the ... drifting eastward along normal wind patterns. Fire is ... from fires is not quite so obvious and its ... type of fire (forest, brush, crop, structure, tires, waste ...
(Date:7/23/2014)... that has the entire country in its grip is affecting ... be responsible for the proliferation of a heat-loving amoeba commonly ... hot springs, which the drought has made warmer than usual ... an infection caused by this parasite after swimming in several ... of an individual and travels to the brain. Nose plugs ...
(Date:7/23/2014)... This news release is available in German . ... shape and stability to cells, drive metabolic processes and ... into complex three-dimensional shapes. Scientists at the Max Planck ... that proteins can be constructed of similar amino acid ... suggests that the proteins that exist today arose from ...
Breaking Biology News(10 mins):Diseases of another kind 2Protein evolution follows a modular principle 2
... to harness DNA,s powerful molecular machinery to build artificial ... pairs of DNA molecules to assemble into complex structures. ... of Technology,* could provide a means of assembling complex ... systems, from the bottom up. While most researchers ...
... This release is available in German . ... supports the sperm in their quest by emitting attractants. Calcium ions ... sperm to move. Together with colleagues from the Max Planck Institute ... of Gttingen, scientists from the caesar research centre in Bonn, an ...
... Columbia is arguably the most important fossil deposit in ... "Explosion," the rapid flowering of complex life from single-celled ... of shells, teeth and bones, the Burgess Shale preserves ... structuresof animals belonging to Earth,s earliest complex ecosystems a ...
Cached Biology News:The shape of things to come: NIST probes the promise of nanomanufacturing using DNA origami 2Sperm can count 2Mechanism for Burgess Shale-type preservation 2
... Pocket Surveyor software provides local instrument ... Surveyor HPLC Systems. The software operates ... popular Windows Pocket PC 2002 O/S ... connect directly to their Surveyor quaternary ...
... separation and fractionation of nucleic-acid ... nuclei from cytosolic proteins A ... greatly facilitating study of low-abundance ... acid binding proteins (e.g., transcription ...
... solution is an isotonic, balanced salt solution. It ... permits the storage of whole blood at refrigerator ... equal volume of blood is collected into a ... mixed. The solution is placed in a refrigerator ...
... fixative useful for routine procedures. Hollandes contains ... and will decalcify small bone specimens. Tissue ... stained successfully with most stains, and the ... blood cell membranes and cosinophil and endocrine ...
Biology Products: